Cargando…

Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na(+)/H(+) exchanger 1: persistent inhibition under various experimental conditions

Detalles Bibliográficos
Autores principales:	Zuurbier, Coert J, Baartscheer, Antonius, Schumacher, Cees A, Fiolet, Jan W T, Coronel, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683702/ https://www.ncbi.nlm.nih.gov/pubmed/33792689 http://dx.doi.org/10.1093/cvr/cvab129

Ejemplares similares

Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
por: Baartscheer, Antonius, et al.
Publicado: (2016)

The Driving Force of the Na(+)/Ca(2+)-Exchanger during Metabolic Inhibition
por: Baartscheer, Antonius, et al.
Publicado: (2011)

Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
por: Chen, Sha, et al.
Publicado: (2023)

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation
por: Uthman, Laween, et al.
Publicado: (2017)

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
por: Uthman, Laween, et al.
Publicado: (2018)

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na(+)/H(+) exchanger-1 or lower [Na(+)](i) in the heart
por: Chung, Yu Jin, et al.
Publicado: (2020)

Empagliflozin inhibits Na(+)/H(+) exchanger activity in human atrial cardiomyocytes
por: Trum, Maximilian, et al.
Publicado: (2020)

Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus
por: Eroglu, Talip E, et al.
Publicado: (2022)

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
por: Chung, Cheng-Chih, et al.
Publicado: (2023)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts
por: Zhang, Hong, et al.
Publicado: (2020)

Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
por: Li, Xiaoling, et al.
Publicado: (2021)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?
por: Zuurbier, Coert J.
Publicado: (2020)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
por: Sanon, Vani P, et al.
Publicado: (2017)

Reducing mitochondrial bound hexokinase II mediates transition from non-injurious into injurious ischemia/reperfusion of the intact heart
por: Nederlof, Rianne, et al.
Publicado: (2017)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
por: Li, Xiaoling, et al.
Publicado: (2022)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II
por: Mustroph, Julian, et al.
Publicado: (2022)

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
por: Tan, Yunke, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
por: Philippaert, Koenraad, et al.
Publicado: (2021)

Proton-dependent inhibition of the cardiac sodium channel Na(v)1.5 by ranolazine
por: Sokolov, S., et al.
Publicado: (2013)

Neurokinin-3 receptor activation selectively prolongs atrial refractoriness by inhibition of a background K(+) channel
por: Veldkamp, Marieke W., et al.
Publicado: (2018)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Inhibition of β-Cell Sodium-Calcium Exchange Enhances Glucose-Dependent Elevations in Cytoplasmic Calcium and Insulin Secretion
por: Hamming, Kevin S.C., et al.
Publicado: (2010)

The effect of inhibition of the Na(+)/H(+) exchanger on the development of hypertrophy in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2011)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

Inhibiting persistent inward sodium currents prevents myotonia
por: Hawash, Ahmed A., et al.
Publicado: (2017)

Dietary Omega-3 Polyunsaturated Fatty Acids Suppress NHE-1 Upregulation in a Rabbit Model of Volume- and Pressure-Overload
por: van Borren, Marcel M. G. J., et al.
Publicado: (2012)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

Novel Treatments from Inhibition of the Intestinal Sodium–Hydrogen Exchanger 3
por: Kovesdy, Csaba P, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ou0lnstvv2a22o2ucsn4f41sjj